ELISpot Human IFN-gamma,12x8 well strip (1 plate)

The Human IFN-gamma Enzyme-Linked ImmunoSpot (ELISpot) assay is a highly sensitive method used to detect and quantify individual cells that secrete specific cytokines or other soluble molecules. This assay is utilized in immunology to monitor cellular immune responses at the single-cell level and reliably detects and measures human IFN-gamma secretion by stimulated effector cells. 8-well strip (12x8) ELISPOT plates offer a flexible, cost-effective alternative to full 96-well plates by allowing smaller-scale assays, reduced reagent use, and easier handling for variable experimental setups. Our pre-coated kits are ready-to-use, helping labs save time and reduce human touchpoints during setup, ideal for accelerating research workflows. IFN-gamma is a dimerized soluble cytokine involved in both innate and adaptive immunity. It is produced primarily by Natural Killer cells during the innate immune response, and by CD4+ Th1 cells and CD8+ T cells during antigen-specific immune responses. As a proinflammatory cytokine, IFN-gamma plays a significant role in activating macrophages and endothelial cells, enhancing their pathogen-killing capabilities. It regulates immune responses by modulating the activity of antigen-presenting cells and T cells. IFN-gamma is critical for both innate and adaptive immunity against viral, bacterial, and protozoal infections due to its ability to inhibit viral replication directly and through its immunostimulatory and immunomodulatory effects. One of its key functions is the induction of MHC class II molecule expression, which improves antigen presentation and immune recognition. Protein function: Produced by lymphocytes activated by specific antigens or mitogens. IFN-gamma, in addition to having antiviral activity, has important immunoregulatory functions. It is a potent activator of macrophages, it has antiproliferative effects on transformed cells and it can potentiate the antiviral and antitumor effects of the type I interferons. [The UniProt Consortium]